Caribou Biosciences Inc (CRBU NASDAQ) stock market data APIs
$1.9318
-0.01(-0.5%)
as of May 8, 2026
Try our APIs with
free plan!
Caribou Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Prev. Close
1.9318
Open
1.9177
High
1.9739
Low
1.8832
52 wk Range
0.7691-3.535
Market Cap
192 M
Shares Outstanding
99 181 K
Revenue
11 203 K
EPS
-0.26
Beta
2.275
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Caribou Biosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Caribou Biosciences Inc data using free add-ons & libraries
Get Caribou Biosciences Inc Fundamental Data
Caribou Biosciences Inc Fundamental data includes:
- Net Revenue: 11 203 K
- EBITDA: -114 156 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-12
- EPS/Forecast: -0.33
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Caribou Biosciences Inc News
New
Qiagen (QGEN) Q1 Earnings and Revenues Lag Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.58 per share a year ago. These figures are a...
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Agilon Health (AGL) one of those stocks right now? By taking a...
Three Best Genomics Stocks for Your Portfolio in 2026
An updated edition of the Feb. 20, 2026, article. Genomics involves a thorough study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). It involves understanding how genes fun...
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) shares soared 35% in the last trading session to close at $23.77. The move was backed by solid volume with far more shares changing hands than in a normal session. This com...
Get Caribou Biosciences Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
